Welcome to our dedicated page for Lakewood-Amedex news (Ticker: LABT), a resource for investors and traders seeking the latest updates and insights on Lakewood-Amedex stock.
Lakewood-Amedex Biotherapeutics reports developments tied to its clinical-stage antimicrobial pipeline and public-company status. News items cover the Bisphosphocin® class, antimicrobial resistance data for the lead compound Nu-3, and the company’s development work for infected diabetic foot ulcers, with additional platform references to complicated urinary tract infection and pulmonary infections.
Company updates also include Nasdaq listing activity under the LABT symbol and governance changes following its direct listing. These announcements describe the company’s transition into a Nasdaq-traded biotechnology issuer while continuing to center on its proprietary antimicrobial platform.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) appointed Joseph Tucker, Ph.D., CEO of Enveric Biosciences (NASDAQ: ENVB), to its Board of Directors on April 28, 2026. The appointment follows Lakewood-Amedex's recent Nasdaq direct listing and is positioned to strengthen governance and strategic capabilities as the company advances its Bisphosphocin® program, including lead candidate Nu-3 for infected diabetic foot ulcers.
Dr. Tucker brings more than two decades of biotech leadership, experience with public listings, M&A, and capital raises, including having raised over $100 million and advancing Enveric's EB-003 toward an anticipated first-in-human trial.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announced its common stock began trading on the Nasdaq Capital Market on April 23, 2026 under the ticker LABT. The company is a clinical-stage biotechnology developer of the Bisphosphocin® class and named Nu-3 as its lead product for infected diabetic foot ulcers (iDFU).
Management said it plans to initiate a Phase 2a clinical trial in iDFU shortly and cited the large U.S. diabetes population and concerns about antibiotic-resistant bacterial strains as drivers for development.